Medtronic (NYSE:MDT) declared today that a recent agreement has been inked with the U.S. Department of Veterans Affairs (VA) for its GI Genius technology. The VA has granted a three-year Indefinite Delivery Indefinite Quantity (IDIQ) deal for GI Genius’ AI-driven endoscopy systems. This translates to an additional nearly 100 units being installed at VA medical facilities nationwide.
This fresh contract builds upon a previous VA agreement from 2022, which saw the deployment of 115 GI Genius units within U.S. VA centers. According to Medtronic, the latest expansion emphasizes its capability of offering cutting-edge healthcare to veterans. The company aims to ensure top-tier diagnostic accuracy in colorectal examinations for countless veterans.
In collaboration with a Service-Disabled Veteran-Owned Small Business (SDVOSB), this deal is the culmination of several years of planning and execution with the VA. Medtronic mentions its preceding experience includes over 360 GI Genius installations spread across upwards of 140 VA centers, including those in Puerto Rico.
Introduced in the U.S. in 2021, GI Genius is an AI-powered polyp detection tool intended to revolutionize gastrointestinal screening by assisting gastroenterologists in conducting colonoscopies. This year, Medtronic introduced next-generation hardware for the GI Genius platform.
Raj Thomas, VP and president of Medtronic’s Endoscopy division, stated, “We are genuinely privileged to extend our partnership with the VA to deliver AI advancements directly to more patients, particularly those veterans who have served our nation with pride. Colorectal cancer remains a frequently diagnosed cancer among veterans, and this collaboration is about more than merely technology—it’s about establishing a new standard in care with AI-driven accuracy for earlier, precise diagnoses. This dedication advances our battle against colorectal cancer and strengthens Medtronic’s mission of offering transformative care to patients worldwide.”
Menu
Menu